Bortezomib and Celecoxib in Treating Patients With Advanced Solid Tumors

Phase 1 Completed 36 enrolled Medical University of South Carolina

Treatment

Summary

RATIONALE: Bortezomib and celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving bortezomib together with celecoxib may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib and celecoxib in treating patients with advanced solid tumors.

Timeline

Start: 2005-03
Primary completion: 2009-01
Completion: 2009-01

Publications

Results Hayslip J, Chaudhary U, Green M, Meyer M, Dunder S, Sherman C, Salzer S, Kraft A, Montero AJ. Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial. BMC Cancer. 2007 Dec 3;7:221. doi: 10.1186/1471-2407-7-221.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bortezomib	Small molecule	—	Intravenous
Subject	Celecoxib	Other / unclassified	200 mg	Oral
Subject	Celecoxib	Other / unclassified	400 mg	Oral

Bortezomib and Celecoxib in Treating Patients With Advanced Solid Tumors

Summary

Timeline

Publications

Drugs

Indications